Futura Medical plc (AIM: FUM) (“Futura” or the “Company”), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology and currently focused on sexual health and pain.
Announces its Annual General Meeting (“AGM”) will be held at 10:00 am on Monday 28 June 2021 at the offices of Liberum, Ropemaker Place, 25 Ropemaker Street, London EC2Y 9LY.
The Board has been closely monitoring the evolving Coronavirus (COVID-19) situation and recognises that UK Government guidance continues to require social distancing and prohibition of mass gatherings.
Only the minimum number of directors who are shareholders will attend in person to ensure a quorum is present. Accordingly, so as to ensure their vote is counted at the AGM, all shareholders are asked to submit a Form of Proxy, instructing the Chairman of the Meeting on how they wish to vote on the proposed resolutions.
The Board recognises the ongoing importance of communication with shareholders at this time. The Company will operate an audio dial-in facility to allow shareholders to listen to the business of the meeting: Shareholders will need to be confirmed as a shareholder or present a letter of representation before details of how to access this facility are released to them via email on the morning of the meeting. You can request access by emailing: investo[email protected] prior to 10:00 am on 24 June 2021.
Shareholders who wish to attend the AGM in person against our recommendation will need to pre-register their intention to do so by email using [email protected] by no later than 10:00 am on 24 June 2021 to ensure access to the venue.
Reminder to vote by proxy
You will not receive a hard copy form of proxy for the 2021 AGM in the post. Instead, you will be able to vote electronically using the link www.signalshares.com. You will need to log into your Signal Shares account, or register if you have not previously done so, to register you will need your Investor Code, this is detailed on your share certificate or available from our Registrar, Link Group. You may request a hard copy form of proxy directly from the registrars, Link Group, on Tel: 0371 664 0391. Proxy votes must be received no later than 10:00 am on 24 June 2021.
The Board will continue to monitor the situation and may, if necessary, need to make further changes to the arrangements for the AGM, including how it is conducted. Shareholders should therefore continue to monitor the Company’s website and announcements.
The Board would like to thank shareholders for their understanding and support during these exceptional circumstances and wish them well during these challenging times.
Futura’s annual report and accounts for the year ended 31 December 2020 (the “Annual Report”) is available to shareholders as an electronic communication pursuant to the Companies Act 2006 and is now available at the Company’s website www.futuramedical.com, along with the Notice of AGM.
About Futura Medical plc
Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® technology. Each DermaSys® formulation is separately patented and specifically tailored for the selected indication and application, as well as being optimised for clinical efficacy, safety, administration and patient convenience. The products are developed for the prescription and consumer healthcare markets as appropriate. Current therapeutic areas are sexual health, including erectile dysfunction, and pain relief. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst minimising risk.
MED3000 is Futura’s topical gel formulation that is a breakthrough treatment for erectile dysfunction (ED) through a unique evaporative mode of action. Futura has conducted a Phase 3 study using MED3000 in ED, referred to as “FM57”. This was a 1,000 patient, dose-ranging, multi-centre, randomised, double blind, placebo-controlled, home use, parallel group study delivering highly statistically significant results compared to pre-treatment baseline, consistently meeting all co-primary endpoints of IIEF, SEP2 and SEP3 (internationally accepted clinical trial endpoints in ED) with over 60% of patients experiencing a clinically meaningful improvement in their ED. MED3000 also begins to work immediately in some patients, with 60% of patients seeing onset of their erection within 10 minutes of application. MED3000 is CE marked in Europe and the UK as a clinically proven topical treatment for adult men with erectile dysfunction.
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.
If anyone reads this article found it useful, helpful? Then please subscribe www.share-talk.com or follow SHARE TALK on our Twitter page for future updates.
Terms of Website Use
All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned